Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.
about
A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolatesFactors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challengeComparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIVRole of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in MacaquesReplicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacyEffects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaquesImproved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac2Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinantsBeyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector.Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus VaccinesEvaluation of cytotoxic T-lymphocyte responses in human and nonhuman primate subjects infected with human immunodeficiency virus type 1 or simian/human immunodeficiency virusEvaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development
P2860
Q33603494-778FF390-8CDD-48F6-AE83-53178F931418Q33649657-81D5885F-1A8A-4C53-AC39-7ED2018E1E92Q33799497-44BC6A55-7383-4CD8-B5EC-B46CC2A1B51FQ33800033-8B378EF1-40D8-468D-B951-CFE38CFC56F0Q33819493-5D65ED44-6694-465A-B62F-4AC59720C4C9Q33911986-9B950EF2-F899-425E-80EA-2233D506BF39Q34485178-8CACBB5A-7A9A-4C8B-B62B-7017B4F8F352Q35021632-172DA4DD-AFF7-44CA-A15C-854C082CB4C2Q35032794-6D613BD4-1847-455F-A58F-090EFF05103CQ35155380-940979A2-EFB3-4938-9802-BD7AEB0CD617Q35182076-0DF8D3DA-6EF9-4065-9687-A4ED210B05F4Q35867976-1C63BFD5-B6FB-4A7C-B8CB-DFFCC99F16ADQ35973518-372071BF-F3DC-4FE5-BCA6-213B7E9927B5Q36071414-1105624D-FD2A-4CD8-8300-9CD7F227EFF9Q36954239-DBFC76E1-6D1D-4167-B90B-9249B5BD9BA1Q37033283-510066FF-7D59-4A74-A5A1-2D899CE0EF7DQ37033311-041AB84F-02F4-4D28-B07B-9D8094AACC9BQ37297052-1E8BE0BA-907A-4D0E-BCB1-D4FD87D38BABQ39582556-551923A4-15A3-48E9-A11F-D5F4204EF10AQ39601073-3C73FF9C-51F5-41A7-A60E-37A79538798AQ42584393-C6C01396-2BF9-4007-A014-CFAF22A0C34DQ56993265-78A9EA7A-B31A-49AB-BFEB-C542935B9761
P2860
Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Vaccine protection against a h ...... human immunodeficiency virus.
@ast
Vaccine protection against a h ...... human immunodeficiency virus.
@en
type
label
Vaccine protection against a h ...... human immunodeficiency virus.
@ast
Vaccine protection against a h ...... human immunodeficiency virus.
@en
prefLabel
Vaccine protection against a h ...... human immunodeficiency virus.
@ast
Vaccine protection against a h ...... human immunodeficiency virus.
@en
P2093
P2860
P1433
P1476
Vaccine protection against a h ...... y human immunodeficiency virus
@en
P2093
A J Conley
E Richardson
F Sinangil
L J Patterson
P2860
P304
10275-10280
P577
1998-12-01T00:00:00Z